Patent applications based on Big Data have risen dramatically from 2021 to 2022. GlobalData, which tracks patent filings, has gathered information worldwide and developed a recent status report. Big data seems to be a key area of disruption in the pharmaceutical industry. Research claims that investors will reap several benefits later if they invest in it now. In this article at Pharmaceutical-Technology, Michael Goodier shares how pharmaceutical companies are using big data for their innovation.
Big Data Patent Applications on the Rise
Switzerland-based F. Hoffmann-La Roche Ltd is one of the top contributors to patent applications in the pharmaceutical industry. It made 63 filings recently. This is a significant jump from the number of filings the company did last year, i.e., 39. This is almost twice the number it managed to make the previous year.
A close second was Johnson & Johnson from the United States (60). Bayer AG from Germany submitted 12 patent applications, while Thermo Fisher Scientific Inc from the United States was able to file nine by the end of the year. Apart from these leading the way, other companies also made their foray into Big Data patent filings. Some of them are already well-known in the pharmaceutical sector. Sanofi (8), AstraZeneca Plc (6), Sartorius AG (6), and Novartis AG (4) are the giants trying their luck in the field. Seegene Inc and IQVIA Holdings Inc also filed three patent applications each.
Ramping Up for Patent Applications
The race does not end by the sheer number of filings. F. Hoffmann-La Roche also accelerated its research initiative on Big Data. Its growth reached a record high of 38.1 percent in three months. That is the highest spike by any company dealing with patents on Big Data.
To view the original article in full, visit the following link: https://www.pharmaceutical-technology.com/analysis/pharmaceutical-industry-companies-are-increasingly-innovating-in-big-data/
